Track market-moving stories before they get noisy

HOUSTON, June 09, 2026 (GLOBE NEWSWIRE) -- Devon Energy Corp. (NYSE: DVN) today provided an updated outlook for the combined company following the recent completion of its transformative merger with Coterra Energy. Supplemental guidance tables for the combined entity are included below and a presentation is available on the company's website at www.devonenergy.com .

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Considering buying DVN stock? Here’s what analysts think:

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Shares of Devon Energy (DVN +1.48%) rose on Wednesday after the hydrocarbon exploration specialist provided investors with an updated operational forecast for 2026.

Image source: Getty Images.

Stronger together Devon completed its $58 billion merger with fellow oil and gas producer Coterra Energy in May. The combination created a more financially sound shale operator with a leading presence in the oil-rich Delaware Basin.

The combined company is on track to produce an average of 1.38 million barrels of oil equivalent per day in 2026. To do so, it plans to spend roughly $4.9 billion this year to bring 460 to 480 net wells online.

Today's Change

(

1.48

%) $

0.66

Current Price

$

45.27

Lucrative cash returns for shareholders Devon's operating strategy prioritizes cost-efficiency and free cash flow generation. Management is targeting $1 billion in ongoing annual pre-tax cost savings by the end of 2027. Devon intends to use the cash its wells produce to strengthen its balance sheet by paying off $1.25 billion of debt.

Devon also plans to pass about 70% of its excess cash on to shareowners via a quarterly fixed dividend of $0.32 per share -- representing a forward annual yield of 2.7% based on its current stock price of $46.60 -- and $8 billion in stock buybacks.

"Today's guidance underscores the strength of our newly combined platform as one of the largest and most efficient E&P [exploration and production] companies," CEO Clay Gaspar said.

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Devon Energy (DVN - Free Report) closed the most recent trading day at $44.61, moving -4.27% from the previous trading session. This change lagged the S&P 500's daily gain of 1.75%. Meanwhile, the Dow experienced a rise of 1.86%, and the technology-dominated Nasdaq saw an increase of 2.54%.

Heading into today, shares of the oil and gas exploration company had lost 0.64% over the past month, lagging the Oils-Energy sector's loss of 0.13% and outpacing the S&P 500's loss of 1.63%.

Investors will be eagerly watching for the performance of Devon Energy in its upcoming earnings disclosure. The company is forecasted to report an EPS of $1.19, showcasing a 41.67% upward movement from the corresponding quarter of the prior year. Alongside, our most recent consensus estimate is anticipating revenue of $6.19 billion, indicating a 44.44% upward movement from the same quarter last year.

Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $4.44 per share and revenue of $25 billion, indicating changes of +13.27% and +45.44%, respectively, compared to the previous year.

Investors should also note any recent changes to analyst estimates for Devon Energy. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 21.92% downward. Devon Energy is currently sporting a Zacks Rank of #3 (Hold).

Looking at its valuation, Devon Energy is holding a Forward P/E ratio of 10.5. Its industry sports an average Forward P/E of 9.87, so one might conclude that Devon Energy is trading at a premium comparatively.

The Oil and Gas - Exploration and Production - United States industry is part of the Oils-Energy sector. This group has a Zacks Industry Rank of 109, putting it in the top 45% of all 250+ industries.

The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.

-

WASHINGTON--(BUSINESS WIRE)--Easterly Government Properties, Inc. (NYSE: DEA) announced today that the Company will release its first quarter 2026 financial results on April 27, 2026.

A conference call will be held Monday, April 27, 2026 at 11:00am Eastern time. The management team will review first quarter performance, discuss recent events and conduct a question-and-answer session.

Attendees that would like to join the call and ask a question may register here to receive the dial-in numbers and unique PIN to access the call. There will also be a live audio, listen-only webcast of the call on the Investor Relations section of Easterly’s Investor Relations website at ir.easterlyreit.com.

Shortly after the call, a replay of the call will be available on the Company’s website for up to twelve months.

About Easterly Government Properties, Inc.

Easterly Government Properties, Inc. (NYSE: DEA) is based in Washington, D.C., and focuses primarily on the acquisition, development and management of Class A commercial properties that are leased to the U.S. Government and its adjacent partners. Easterly’s experienced management team brings specialized insight into the strategy and needs of mission-critical U.S. Government agencies for properties leased to such agencies either directly or through the U.S. General Services Administration (GSA). For further information on the company and its properties, please visit www.easterlyreit.com.

More News From Easterly Government Properties, Inc.

Back to Newsroom

Posted by Defense World Staff on Apr 27th, 2026

HG (OTCMKTS:STLY – Get Free Report) and Easterly Government Properties (NYSE:DEA – Get Free Report) are both small-cap finance companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, earnings, risk and analyst recommendations.

Profitability This table compares HG and Easterly Government Properties’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets HG 10.38% 3.91% 2.97% Easterly Government Properties 3.87% 0.94% 0.39% Valuation and Earnings This table compares HG and Easterly Government Properties”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HG $14.74 million 1.46 $1.53 million $0.35 12.14 Easterly Government Properties $336.10 million 3.25 $13.00 million $0.28 84.15 Easterly Government Properties has higher revenue and earnings than HG. HG is trading at a lower price-to-earnings ratio than Easterly Government Properties, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility HG has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500. Comparatively, Easterly Government Properties has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500.

Analyst Ratings This is a summary of recent recommendations and price targets for HG and Easterly Government Properties, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HG 0 0 0 0 0.00 Easterly Government Properties 1 3 1 0 2.00 Easterly Government Properties has a consensus target price of $23.49, suggesting a potential downside of 0.30%. Given Easterly Government Properties’ stronger consensus rating and higher possible upside, analysts clearly believe Easterly Government Properties is more favorable than HG.

Institutional & Insider Ownership 1.7% of HG shares are owned by institutional investors. Comparatively, 86.5% of Easterly Government Properties shares are owned by institutional investors. 75.0% of HG shares are owned by insiders. Comparatively, 6.5% of Easterly Government Properties shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary Easterly Government Properties beats HG on 9 of the 14 factors compared between the two stocks.

About HG (Get Free Report)

HG Holdings, Inc. engages in the title insurance and real estate businesses in the United States. It operates through four segments: Title Insurance Services, Reinsurance, Management Services, and Real Estate. The company provides title insurance, closing and/or escrow, and similar or related services in connection with residential and commercial real estate transactions. It also owns and operates a portfolio of single-tenant properties leased for the occupancy by U.S. government tenant agencies and sub-agencies, such as the Federal Bureau of Investigation, the Department of Veterans affairs, the Drug Enforcement Administration, Immigration & Customs Enforcement, the Social Security Administration, and the Department of Transportation. In addition, the company provides excess-of-loss reinsurance coverage related to catastrophic weather risk in Texas; and management advisory services, such as formation, operational, and restructuring services. The company was formerly known as Stanley Furniture Company, Inc. and changed its name to HG Holdings, Inc. in March 2018. HG Holdings, Inc. was incorporated in 1984 and is headquartered in Charlotte, North Carolina.

About Easterly Government Properties (Get Free Report)

Easterly Government Properties, Inc. (NYSE: DEA) is based in Washington, D.C., and focuses primarily on the acquisition, development and management of Class A commercial properties that are leased to the U.S. Government. Easterly’s experienced management team brings specialized insight into the strategy and needs of mission-critical U.S. Government agencies for properties leased to such agencies either directly or through the U.S. General Services Administration (GSA).

Receive News & Ratings for HG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HG and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEHead-To-Head Analysis: CV (OTCMKTS:CVHL) & Ellington Financial (NYSE:EFC)

NEXT HEADLINE »Akbank Turk Anonim Sirketi (OTCMKTS:AKBTY) and China Merchants Bank (OTCMKTS:CIHKY) Critical Review

WASHINGTON--(BUSINESS WIRE)--Easterly Government Properties, Inc. (NYSE: DEA) (the “Company” or “Easterly”), a fully integrated real estate investment trust (“REIT”) focused primarily on the acquisition, development and management of Class A commercial properties leased to the U.S. Government and its adjacent partners, today announced its results of operations for the quarter ended March 31, 2026.

Highlights for the Quarter Ended March 31, 2026:

Net income of $1.4 million, or $0.03 per share on a fully diluted basis Core FFO of $37.1 million, or $0.77 per share on a fully diluted basis Acquired a 297,713 square foot campus leased primarily to the Commonwealth of Virginia with lease expirations ranging from 2027 to 2036. Entered into a mezzanine construction loan agreement to lend $7.0 million to a developer that will accrue interest monthly at a fixed market rate of 12.00% per annum. Issued an aggregate of 94,170 shares of the Company's common stock in settlement of previously entered into forward sales transactions through the Company's $300.0 million ATM Program launched in June 2021 (the “2021 ATM Program”). These shares were then physically settled in the same quarter at a weighted average price per share of $23.01, raising net proceeds to the Company of approximately $2.1 million. “We entered 2026 with clear priorities, and the first quarter demonstrates progress toward them,” said Darrell Crate, President & CEO of Easterly Government Properties. “Stable operating performance and the successful execution of our first mezzanine investment highlight our strategic approach to capital allocation and earnings growth.”

Portfolio Operations

As of March 31, 2026, the Company or its joint venture owned 106 operating properties in the United States encompassing approximately 10.7 million leased square feet, including 93 operating properties that were leased primarily to U.S. Government tenant agencies, eight operating properties leased primarily to tenant agencies of a U.S. state or local government and five operating properties that were entirely leased to private tenants. In addition, the Company wholly owned three properties in development that the Company expects will encompass approximately 0.2 million rentable square feet upon completion.

The first development project, located in Flagstaff, Arizona, is currently under construction and, once complete, a 20-year lease with the GSA is expected to commence for the beneficial use of the United States Judiciary. The second project, located in Fort Myers, Florida, is currently under construction and, once complete, a 25-year lease with the Florida Department of Law Enforcement is expected to commence for their beneficial use. The third project, located in Medford, Oregon, is currently under construction and, once complete, a 20-year lease with the GSA is expected to commence for the beneficial use of the United States Judiciary.

As of March 31, 2026, the portfolio had a weighted average age of 16.9 years, based upon the date properties were built or renovated-to-suit, and had a weighted average remaining lease term of 9.4 years.

Acquisitions Activity

Acquisitions

On January 16, 2026, the Company acquired a 297,713 square foot campus consisting of three assets near Richmond, Virginia. The assets are leased primarily to the Commonwealth of Virginia and have lease expirations ranging from 2027 to 2036.

Balance Sheet and Capital Markets Activity

As of March 31, 2026, the Company had total indebtedness of approximately $1.7 billion comprised of $245.1 million outstanding on its senior unsecured revolving credit facility, $100.0 million outstanding on its 2016 term loan facility, $200.0 million outstanding on its 2018 term loan facility, $1.0 billion of senior unsecured notes, and $150.5 million of mortgage debt (excluding unamortized premiums and discounts and deferred financing fees). The Company's outstanding debt had a weighted average maturity of 3.9 years and a weighted average interest rate of 4.6%. Further, the Company's Net Debt to total enterprise value was 62.5% and its Adjusted Net Debt to annualized quarterly pro forma EBITDA ratio was 7.3x.

Dividend

On April 22, 2026, the Board of Directors of Easterly approved a cash dividend for the first quarter of 2026 in the amount of $0.45 per common share. The dividend will be payable May 21, 2026 to shareholders of record on May 7, 2026.

Guidance

This guidance is forward-looking and reflects management’s view of current and future market conditions. The Company’s actual results may differ materially from this guidance.

Outlook for the 12 Months Ending December 31, 2026

The Company is raising the lower end of its guidance for full-year 2026 Core FFO per share on a fully diluted basis at a range of $3.06 - $3.12.

Low

High

Net income (loss) per share – fully diluted basis

$

0.36

0.42

Plus: Company’s share of real estate depreciation and amortization

$

2.68

2.68

FFO per share – fully diluted basis

$

3.04

3.10

Plus: Company’s share of depreciation of non-real estate assets

$

0.02

0.02

Core FFO per share – fully diluted basis

$

3.06

3.12

This guidance assumes approximately $50 million of wholly owned acquisitions and $50 - $100 million of gross development-related investment during 2026.

Non-GAAP Supplemental Financial Measures

This section contains definitions of certain non-GAAP financial measures and other terms that the Company uses in this press release and, where applicable, the reasons why management believes these non-GAAP financial measures provide useful information to investors about the Company’s financial condition and results of operations and the other purposes for which management uses the measures. These measures should not be considered in isolation or as a substitute for measures of performance in accordance with GAAP. A reconciliation of the differences between each non-GAAP financial measure and the comparable GAAP financial measure are included in this press release following the consolidated financial statements. Additional detail can be found in the Company’s most recent annual report on Form 10-K and quarterly report on Form 10-Q, as well as other documents filed with or furnished to the Securities and Exchange Commission from time to time. We present certain financial information and metrics “at Easterly’s Share,” which is calculated on an entity-by-entity basis. “At Easterly’s Share” information, which we also refer to as being “at share,” “pro rata,” or “our share” is not, and is not intended to be, a presentation in accordance with GAAP.

Cash Available for Distribution (CAD) is a non-GAAP financial measure that is not intended to represent cash flow for the period and is not indicative of cash flow provided by operating activities as determined under GAAP. CAD is calculated in accordance with the current Nareit definition as FFO minus normalized recurring real estate-related expenditures and other non-cash items, nonrecurring expenditures and the unconsolidated real estate venture’s allocated share of these adjustments. CAD is presented solely as a supplemental disclosure because the Company believes it provides useful information regarding the Company’s ability to fund its dividends. Because all companies do not calculate CAD the same way, the presentation of CAD may not be comparable to similarly titled measures of other companies.

Core Funds from Operations (Core FFO) adjusts FFO to present an alternative measure of the Company's operating performance, which, when applicable, excludes items which it believes are not representative of ongoing operating results, such as liability management related costs (including losses on extinguishment of debt and modification costs), catastrophic event charges, depreciation of non-real estate assets, provision for (recovery of) credit losses, and the unconsolidated real estate venture's allocated share of these adjustments. In future periods, the Company may also exclude other items from Core FFO that it believes may help investors compare its results. The Company believes Core FFO more accurately reflects the ongoing operational and financial performance of the Company's core business.

EBITDA is calculated as the sum of net income (loss) before interest expense, taxes, depreciation and amortization, (gain) loss on the sale of operating properties, impairment loss, and the unconsolidated real estate venture’s allocated share of these adjustments. EBITDA is not intended to represent cash flow for the period, is not presented as an alternative to operating income as an indicator of operating performance, should not be considered in isolation or as a substitute for measures of performance prepared in accordance with GAAP, is not indicative of operating income or cash provided by operating activities as determined under GAAP and may be presented on a pro forma basis. EBITDA is presented solely as a supplemental disclosure with respect to liquidity because the Company believes it provides useful information regarding the Company's ability to service or incur debt. Because all companies do not calculate EBITDA the same way, the presentation of EBITDA may not be comparable to similarly titled measures of other companies.

Funds From Operations (FFO) is defined, in accordance with the Nareit FFO White Paper - 2018 Restatement, as net income (loss), calculated in accordance with GAAP, excluding depreciation and amortization related to real estate, gains and losses from the sale of certain real estate assets, gains and losses from change in control and impairment write-downs of certain real estate assets and investments in entities when the impairment is directly attributable to decreases in the value of depreciable real estate held by the entity. FFO includes the Company’s share of FFO generated by unconsolidated affiliates. FFO is a widely recognized measure of REIT performance. Although FFO is a non-GAAP financial measure, the Company believes that information regarding FFO is helpful to shareholders and potential investors.

Net Debt and Adjusted Net Debt Net Debt represents the Company's consolidated debt and its share of unconsolidated debt adjusted to exclude its share of unamortized premiums and discounts and deferred financing fees, less its share of cash and cash equivalents and property acquisition closing escrow, net of deposit. By excluding these items, the result provides an estimate of the contractual amount of borrowed capital to be repaid, net of cash available to repay it. The Company believes this calculation constitutes a beneficial supplemental non-GAAP financial disclosure to investors in understanding its financial condition. Adjusted Net Debt is Net Debt reduced by 1) for each project under construction or in design, the lesser of i) outstanding lump-sum reimbursement amounts and ii) the cost to date, 2) 40% times the amount by which the cost to date exceeds total lump-sum reimbursement amounts for each project under construction or in design and 3) outstanding lump-sum reimbursement amounts for projects previously completed. These adjustments are made to 1) remove the estimated portion of each project under construction, in design or previously completed that has been financed with debt which may be repaid with outstanding cost reimbursement payments from the US Government and 2) remove the estimated portion of each project under construction or in design, in excess of total lump-sum reimbursements, that has been financed with debt but has not yet produced earnings. See page 28 of the Company’s Q1 2026 Supplemental Information Package for further information. The Company’s method of calculating Net Debt and Adjusted Net Debt may be different from methods used by other REITs and may be presented on a pro forma basis. Accordingly, the Company's method may not be comparable to such other REITs.

Other Definitions

Fully diluted basis assumes the exchange of all outstanding common units representing limited partnership interests in the Company’s operating partnership, or common units, the full vesting of all shares of restricted stock, and the exchange of all earned and vested LTIP units in the Company’s operating partnership for shares of common stock on a one-for-one basis, which is not the same as the meaning of “fully diluted” under GAAP.

Conference Call Information

The Company will host a webcast and conference call at 11:00 am Eastern time on April 27, 2026 to review the first quarter 2026 performance, discuss recent events and conduct a question-and-answer session. A live webcast will be available in the Investor Relations section of the Company’s website. Shortly after the webcast, a replay of the webcast will be available on the Investor Relations section of the Company's website for up to twelve months. Please note that the full text of the press release and supplemental information package are also available through the Company’s website at ir.easterlyreit.com.

About Easterly Government Properties, Inc.

Easterly Government Properties, Inc. (NYSE: DEA) is based in Washington, D.C., and focuses primarily on the acquisition, development and management of Class A commercial properties that are leased to the U.S. Government. Easterly’s experienced management team brings specialized insight into the strategy and needs of mission-critical U.S. Government agencies for properties leased to such agencies either directly or through the U.S. General Services Administration (GSA). For further information on the company and its properties, please visit www.easterlyreit.com.

Forward Looking Statements

We make statements in this press release that are considered “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions and include our guidance with respect to Net income (loss) and Core FFO per share on a fully diluted basis. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement in this press release for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation: risks associated with our dependence on the U.S. Government and its agencies for substantially all of our revenues, including credit risk and risk that the U.S. Government reduces its spending on real estate or that it changes its preference away from leased properties, including as a result of or in connection with any shutdown of the U.S. Government; risks associated with ownership and development of real estate; the risk of decreased rental rates or increased vacancy rates; the loss of key personnel; general volatility of the capital and credit markets and the market price of our common stock; the risk we may lose one or more major tenants; difficulties in completing and successfully integrating acquisitions; failure of acquisitions or development projects to occur at anticipated levels or yield anticipated results; risks associated with our joint venture activities; risks associated with actual or threatened terrorist attacks; intense competition in the real estate market that may limit our ability to attract or retain tenants or re-lease space; insufficient amounts of insurance or exposure to events that are either uninsured or underinsured; uncertainties and risks related to adverse weather conditions, natural disasters and climate change; exposure to liability relating to environmental and health and safety matters; limited ability to dispose of assets because of the relative illiquidity of real estate investments and the nature of our assets; exposure to litigation or other claims; risks associated with breaches of our data security; risks associated with our indebtedness, including failure to refinance current or future indebtedness on favorable terms, or at all, failure to meet the restrictive covenants and requirements in our existing and new debt agreements, fluctuations in interest rates and increased costs to refinance or issue new debt; risks associated with derivatives or hedging activity; risks associated with mortgage debt or unsecured financing or the unavailability thereof, which could make it difficult to finance or refinance properties and could subject us to foreclosure; adverse impacts from any future pandemic, epidemic or outbreak of any highly infectious disease on the U.S., regional and global economies and our financial condition and results of operations; and other risks and uncertainties detailed in the “Risk Factors” section of our Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (SEC) on February 23, 2026, and under the heading “Risk Factors” in our other public filings. In addition, our anticipated qualification as a real estate investment trust involves the application of highly technical and complex provisions of the Internal Revenue Code of 1986, or the Code, and depends on our ability to meet the various requirements imposed by the Code through actual operating results, distribution levels and diversity of stock ownership. We assume no obligation to update publicly any forward looking statements, whether as a result of new information, future events or otherwise.

Balance Sheet

(Unaudited, in thousands, except share amounts)

March 31, 2026

December 31, 2025

Assets

Real estate properties, net

$

2,738,755

$

2,714,650

Cash and cash equivalents

2,017

23,374

Restricted cash

10,661

10,257

Tenant accounts receivable

73,041

51,493

Investment in unconsolidated real estate venture

304,070

304,721

Real estate loans receivable, net and investment in sales-type lease, net

44,462

34,286

Intangible assets, net

189,534

183,911

Prepaid expenses and other assets

57,520

57,078

Total assets

$

3,420,060

$

3,379,770

Liabilities

Revolving credit facility

245,050

199,050

Term loan facilities, net

297,479

297,200

Notes payable, net

1,019,132

1,018,884

Mortgage notes payable, net

150,054

151,191

Intangible liabilities, net

13,598

11,959

Deferred revenue

230,031

219,201

Interest rate swaps

1,010

3,034

Accounts payable, accrued expenses and other liabilities

108,203

109,686

Total liabilities

2,064,557

2,010,205

Equity

Common stock, par value $0.01, 80,000,000 shares authorized, 46,444,374 and 46,303,469 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively

464

463

Additional paid-in capital

1,961,587

1,958,412

Retained earnings

146,222

144,857

Cumulative dividends

(796,880

)

(776,022

)

Accumulated other comprehensive loss

(2,554

)

(4,578

)

Total stockholders' equity

1,308,839

1,323,132

Non-controlling interest in Operating Partnership

46,664

46,433

Total equity

1,355,503

1,369,565

Total liabilities and equity

$

3,420,060

$

3,379,770

Income Statement

(Unaudited, in thousands, except share and per share amounts)

Three Months Ended

March 31, 2026

March 31, 2025

Revenues

Rental income

$

88,593

$

75,546

Tenant reimbursements

804

1,026

Asset management income

646

622

Other income

1,502

1,481

Total revenues

91,545

78,675

Expenses

Property operating

20,536

17,799

Real estate taxes

8,532

7,957

Depreciation and amortization

33,221

26,797

Acquisition costs

649

307

Corporate general and administrative

8,495

6,215

Provision for (recovery of) credit losses

196

(238

)

Total expenses

71,629

58,837

Other income (expense)

Income from unconsolidated real estate venture

1,664

1,822

Interest expense, net

(20,166

)

(18,377

)

Net income

1,414

3,283

Non-controlling interest in Operating Partnership

(49

)

(156

)

Net income available to Easterly Government

Properties, Inc.

$

1,365

$

3,127

Net income available to Easterly Government

Properties, Inc. per share:

Basic

$

0.02

$

0.07

Diluted

$

0.02

$

0.07

Weighted-average common shares outstanding:

Basic

46,260,517

43,224,145

Diluted

46,453,599

43,372,207

Net income, per share - fully diluted basis

$

0.03

$

0.07

Weighted average common shares outstanding -

fully diluted basis

47,996,434

45,420,667

EBITDA

(Unaudited, in thousands)

Three Months Ended

March 31, 2026

March 31, 2025

Net income

$

1,414

$

3,283

Depreciation and amortization

33,221

26,797

Interest expense

20,166

18,377

Tax expense

111

163

Unconsolidated real estate venture allocated share of above adjustments

2,340

2,341

EBITDA

$

57,252

$

50,961

Pro forma adjustments(1)

188

Pro forma EBITDA

$

57,440

(1) Pro forma assuming a full quarter of operations from the three operating properties acquired in the first quarter of 2026.

FFO and CAD

(Unaudited, in thousands, except share and per share amounts)

Three Months Ended

March 31, 2026

March 31, 2025

Net income

$

1,414

$

3,283

Depreciation of real estate assets

32,955

26,546

Unconsolidated real estate venture allocated share of above adjustments

2,281

2,279

FFO

$

36,650

$

32,108

Adjustments to FFO:

Loss on extinguishment of debt and modification costs

$

-

$

900

Provision for (recovery of) credit losses

196

(238

)

Natural disaster event expense, net of recovery

15

23

Depreciation of non-real estate assets

267

251

Unconsolidated real estate venture allocated share of above adjustments

17

17

Core FFO

$

37,145

$

33,061

FFO, per share - fully diluted basis

$

0.76

$

0.71

Core FFO, per share - fully diluted basis

$

0.77

$

0.73

Core FFO

$

37,145

$

33,061

Straight-line rent and other non-cash adjustments

(2,007

)

251

Amortization of above-/below-market leases

(435

)

(518

)

Amortization of deferred revenue

(3,704

)

(1,762

)

Non-cash interest expense

939

759

Non-cash compensation

2,097

1,421

Natural disaster event expense, net of recovery

(15

)

(23

)

Principal amortization

(1,190

)

(1,127

)

Maintenance capital expenditures

(657

)

(285

)

Contractual tenant improvements

(49

)

(612

)

Unconsolidated real estate venture allocated share of above adjustments

29

(20

)

Cash Available for Distribution (CAD)

$

32,153

$

31,145

Weighted average common shares outstanding - fully diluted basis

47,996,434

45,420,667

Net Debt and Adjusted Net Debt

(Unaudited, in thousands)

March 31, 2026

Total Debt(1)

$

1,720,560

Less: Cash and cash equivalents

(3,964

)

Net Debt

$

1,716,596

Less: Adjustment for development projects(2)

(49,099

)

Adjusted Net Debt

$

1,667,497

1 Excludes unamortized premiums / discounts and deferred financing fees.

2 See definition of Adjusted Net Debt on Page 4 of this release.

More News From Easterly Government Properties, Inc.

, /PRNewswire/ -- Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced that it has filed applications with the U.S. Drug Enforcement Administration (DEA) to register certain state‑licensed medical marijuana operations pursuant to the expedited registration pathway established by the recent rescheduling of medical marijuana to Schedule III under the Controlled Substances Act.

"DEA registration for our medical business marks a historic step forward for Trulieve and the patients we serve," said Trulieve Chief Executive Officer Kim Rivers. "With over 200 dispensaries serving only medical patients, Trulieve is uniquely positioned to set the bar as a responsible operator in U.S. cannabis."

Following the reclassification of medical marijuana to Schedule III, the DEA established an expedited registration process for eligible state‑licensed medical marijuana operators. For operators that apply within 60 days, licensure to manufacture, distribute, and dispense Schedule III medical marijuana products is deemed approved unless otherwise notified.

About Trulieve
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S., with established hubs in the Northeast, Southeast, and Southwest, anchored by cornerstone markets in Arizona, Florida, Ohio, and Pennsylvania. Driven by a core mission to expand access to cannabis, Trulieve serves customers with innovative, high-quality branded products and exceptional experiences. With scaled operations in attractive markets and targeted expansion through its hub strategy, Trulieve is poised for accelerated growth. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com.

Facebook: @Trulieve   
Instagram: @Trulieve
X: @Trulieve

Investor and Media Contact
Christine Hersey, Chief Corporate Affairs and Strategy Officer
+1 (424) 202-0210
[email protected]

SOURCE Trulieve Cannabis Corp.

-

WASHINGTON--(BUSINESS WIRE)--Easterly Government Properties, Inc. (NYSE: DEA), a fully integrated real estate investment trust focused primarily on the acquisition, development and management of Class A commercial properties leased to the U.S. Government and its adjacent partners, announced today that management will participate in investor meetings at Wells Fargo’s 29th Annual Real Estate Securities Conference in Charleston, South Carolina on May 4, 2026.

Electronic copies of the written materials to be provided to investors in connection with the meetings can be found in the Presentation section of the Company’s Investor Relations website at ir.easterlyreit.com.

About Easterly Government Properties, Inc.

Easterly Government Properties, Inc. (NYSE: DEA) is based in Washington, D.C., and focuses primarily on the acquisition, development and management of Class A commercial properties that are leased to the U.S. Government and its adjacent partners. Easterly’s experienced management team brings specialized insight into the strategy and needs of mission-critical U.S. Government agencies for properties leased to such agencies either directly or through the U.S. General Services Administration (GSA). For further information on the company and its properties, please visit www.easterlyreit.com.

More News From Easterly Government Properties, Inc.

Back to Newsroom

VANCOUVER, British Columbia, May 08, 2026 (GLOBE NEWSWIRE) -- LEEF Brands, Inc. (CSE: LEEF) (OTCQB: LEEEF) (“LEEF” or the “Company”), a rapidly growing cannabis company, today announced that it has filed applications for registration with the U.S. Drug Enforcement Administration (“DEA”) following recent federal cannabis rescheduling developments.

The applications are a key step in positioning LEEF to participate in potential interstate commerce and international export channels as regulatory frameworks evolve. To support this process, LEEF has engaged attorney Shane Pennington, Partner at Blank Rome, and a leading expert in DEA licensing and regulatory strategy.

“Rescheduling is the most significant change our industry has seen in over 50 years,” said Micah Anderson, Chief Executive Officer of LEEF Brands. “We’ve spent years building a low-cost, vertically integrated platform designed for this moment. For the first time in this industry’s history, federal policy is moving in a direction that makes what we do more valuable, not less.”

LEEF is currently profitable operating in California — one of the most competitive and lowest-priced cannabis markets in the world — driven by its vertically integrated model and in-house cultivation at Salisbury Canyon Ranch. Interstate and global exports are expected to provide an opportunity to sell into other markets at meaningfully higher prices.

LEEF’s platform includes one of the world’s largest cannabis farms and one of the highest-capacity, most sophisticated extraction labs. The Company believes this platform positions it to supply both the U.S. and global markets. While regulatory timelines remain uncertain, LEEF is actively preparing to participate as opportunities emerge.

About LEEF Brands, Inc.
LEEF Brands, Inc. is a leading California and New York-based extraction and manufacturing cannabis company. With a comprehensive supply chain, innovative manufacturing processes, a dynamic bulk concentrate portfolio, and a growing line of branded products, LEEF powers some of the largest cannabis brands in the United States. For more information, visit www.leefbrands.com.

Forward-Looking Statements
This news release contains certain forward-looking information and forward-looking statements, as defined in applicable securities laws (collectively, “forward-looking statements”), including, but not limited to, statements regarding the Company’s future financial condition, operations, and objectives.

Forward-looking statements reflect current expectations or beliefs regarding future events or the Company’s future performance or financial results. All statements other than statements of historical fact are forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “continues”, “forecasts”, “projects”, “predicts”, “intends”, “anticipates”, “targets” or “believes”, or variations of, or the negatives of, such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “should”, “might” or “will” be taken, occur or be achieved. All forward-looking statements, including those herein, are qualified by this cautionary statement.

Although the Company believes that the expectations expressed in such statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the statements.

There are certain factors that could cause actual results to differ materially from those in the forward-looking information, including, but not limited to, the risks disclosed in the Company’s public filings on the Company’s issuer profile on SEDAR+ at www.sedarplus.ca. Accordingly, readers should not place undue reliance on forward-looking statements.

LEEF Brands, Inc.
Per: Jesse Redmond
Chief Strategy & Investor Relations Officer
Phone: +1 (805) 717-9327
Email: [email protected]

Compass Pathways Announces First Quarter 2026 Financial Results and Business Highlights Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported first quarter 2026 financial results and business highlights.

“With regulatory acceleration unfolding, we are working diligently towards our goal of completing the filing of a robust clinical package by Q4 and securing COMP360 approval,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “COMP360 represents a fundamentally different approach for patients with treatment resistant depression, unlike any other treatment approved today. Its transformative clinical profile has the potential to change what patients can expect in terms of both rapid and durable relief, and we are ready to deliver for those who have waited far too long for better options.”

Business Highlights

Accelerated regulatory path

Approval timelines are tracking to Compass’ fastest projected expectations, supported by regulatory acceleration including a rolling New Drug Application (NDA) submission and the Commissioner’s National Priority Review Voucher (CNPV).

NDA rolling submission underway: FDA granted Compass NDA rolling submission and review request, based on strength of positive Phase 3 data. Rolling submission and review are underway, with sections of the NDA already submitted. 26-week (Part B) data from COMP006, expected in early Q3 2026. The final NDA submission remains on track for Q4, aligned with the Company’s previously defined accelerated timing. Post-NDA filing momentum: CNPV awarded for COMP360, Compass’ proprietary formulation of synthetic psilocybin for TRD, which has the potential to accelerate filing review time to be completed within 1-2 months. White House Executive Order on psychedelics treatments directs the Drug Enforcement Administration (DEA) to initiate and complete review of psychedelic treatment that has successfully completed Phase 3 trials so that rescheduling may proceed as quickly as possible. Advancing toward commercial launch

Launch readiness: Compass will be launch ready by the end of the year and has assembled a highly experienced commercial leadership team. The team is advancing comprehensive launch preparedness efforts, including KOL and HCP education, payer engagement, and ongoing initiatives to support a timely federal and state rescheduling process. Delivery infrastructure readiness: COMP360 is expected to fit seamlessly across diverse healthcare settings within the current infrastructure of over 7,300 centers1 offering multi-hour treatments Treatment centers are growing rapidly, and existing centers are already scaling in anticipation of a COMP360 launch and additional multi-hour psychedelic treatments coming to market. COMP360’s transformative clinical profile

COMP360 has the potential to offer a highly differentiated, transformative clinical profile and is expected to be a blockbuster opportunity. COMP360 is the first classic psychedelic2 to consistently achieve a highly statistically significant result and clinically meaningful effect in 3 large late-stage trials involving more than 1,000 participants living with TRD, with a generally well-tolerated and safe profile. COMP360 demonstrates effects as quickly as within one day after administration with durability lasting at least through 6 months for those who achieve a clinically meaningful response after one or two doses. Financial Highlights

Research and development expenses were $26.5 million for the three months ended March 31, 2026, compared with $30.9 million during the same period in 2025. The decrease was primarily driven by lower development expenses, reflecting reduced clinical trial costs as our Phase 3 program for COMP360 psilocybin therapy in TRD progresses toward completion, as well reduced discovery program expenses following the termination of certain programs in connection with the reorganization that took place in the fourth quarter of 2024 and the related contract terminations in 2025. General and administrative expenses were $16.4 million for the three months ended March 31, 2026, compared with $18.7 million during the same period in 2025. The decrease was primarily due to lower legal and professional fees, driven by higher financing-related costs in 2025, including those associated with warrant issuances, which were expensed as incurred, whereas a greater portion of such costs in 2026 were capitalized. This decrease was partially offset by increased consulting and legal advisory expenses. Net income for the three months ended March 31, 2026, was $91.2 million, or $0.71 net income per share (basic) and $0.30 net loss per share (diluted), compared with a net loss of $17.9 million, or $0.20 net loss per share (basic) and $0.24 net loss per share (diluted), during the same period in 2025. The increase in net income was primarily driven by a $130.9 million non-cash gain on fair value adjustment related to our warrants, compared with $19.5 million during the same period in 2025. As the fair value of the warrants fluctuates with our share price, this adjustment can result in significant variability in our reported net income or net loss. Cash and cash equivalents were $466.0 million as of March 31, 2026, compared with $149.6 million as of December 31, 2025. Debt was $50.5 million as of March 31, 2026, compared with $31.6 million as of December 31, 2025. Financial Guidance

The current cash position is expected to be sufficient to fund operating expenses and capital expenditure requirements into 2028.

About Compass Pathways

Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational COMP360 synthetic psilocybin treatment, potentially a first in class treatment. COMP360 has Breakthrough Therapy designation from the US Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression (TRD).

Compass is headquartered in London, UK, with offices in New York in the US. We envision a world where mental health means not just the absence of illness but the ability to thrive.

Forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. In some cases, forward-looking statements can be identified by terminology such as “may”, “might”, “will”, “could”, “would”, “should”, “expect”, “intend”, “plan”, “objective”, “anticipate”, “believe”, “contemplate”, “estimate”, “predict”, “potential”, “continue” and “ongoing,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements relating to, among other things, statements regarding our expectations regarding our financial guidance; our business strategy and goals; our expectations and projections about the company’s future cash needs and financial results; our expectations regarding the safety or efficacy of our investigational COMP360 psilocybin treatment, including as a treatment of TRD or PTSD; our plans and expectations regarding our clinical trials, including our phase 3 trials in TRD and our phase 2b/3 trial in PTSD; our expectations regarding the time periods for the release of data from Part B of the COMP006 Phase 3 trial for TRD; any implication that past results will be predictive of future results; our expectations regarding the timing of our rolling submission of a new drug application, or NDA, for COMP360 psilocybin treatment in TRD and the timing of the review by the Food and Drug Administration, or FDA, of such NDA, including potential acceleration due to the grant of rolling review and award of a Commissioner’s National Priority Voucher, or CNPV, for COMP360 psilocybin treatment in TRD; the potential for the pivotal phase 3 program in TRD to support regulatory filings and approvals on an accelerated basis or at all; our expectations regarding potential commercial launch timelines and our commercial readiness; our efforts and our ability to obtain regulatory approval and adequate coverage and reimbursement; our ability to transition from a clinical-stage to a commercial-stage organization and effectively launch a commercial product, if regulatory approval is obtained, on an accelerated timeline or at all; and our expectations regarding the benefits of our investigational COMP360 psilocybin treatment, including as a treatment of TRD or PTSD. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Compass’s control and which could cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these forward-looking statements.

These risks, uncertainties, and other factors include, among others: uncertainties associated with risks related to clinical development which is a lengthy and expensive process with uncertain outcomes, and therefore our clinical trials may be delayed or terminated and may be more costly than expected; the full results and safety data from our Phase 3 clinical trials in TRD may not be consistent with the preliminary results to date; our need for additional funding to achieve our business goals and if we are unable to obtain this funding when needed and on acceptable terms, we could be forced to delay, limit or terminate our clinical trials; that the rolling review process and/or the Commissioner's National Priority Voucher pilot program may not actually lead to a faster FDA review or approval process; our efforts to obtain FDA approval, or approval from regulatory authorities in other jurisdictions, for our investigational COMP360 psilocybin treatment on an accelerated basis, or at all, may be unsuccessful; our efforts to commercialize and obtain coverage and reimbursement for our investigational COMP360 psilocybin treatment, if approved, may be unsuccessful; the risk that our strategic collaborations will not continue or will not be successful; and our ability to retain key personnel; and those risks and uncertainties described under the heading “Risk Factors” in Compass’s most recent annual report on Form 10-K or quarterly report on Form 10-Q, the prospectus supplement related to the proposed public offering we plan to file and in other reports we have filed with the U.S. Securities and Exchange Commission (“SEC”), which are available on the SEC’s website at www.sec.gov. Except as required by law, Compass disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Compass’s current expectations and speak only as of the date hereof.

References

Data on file For the definition of classic psychedelic, see Vollenweider, F.X. and Smallridge, J.W., 2022. Classic psychedelic drugs: update on biological mechanisms. Pharmacopsychiatry, 55(03), pp.121-138 Enquiries

Media: Dana Sultan-Rothman, [email protected]

Investors: Stephen Schultz, [email protected], +1 401 290 7324

COMPASS PATHWAYS PLC

Condensed Consolidated Balance Sheets

(unaudited)

(in thousands, except share and per share amounts)

(expressed in U.S. Dollars, unless otherwise stated)

March 31,

December 31,

2026

2025

ASSETS

CURRENT ASSETS:

Cash and cash equivalents

$466,010

$149,608

Restricted cash

379

379

Prepaid expenses and other current assets

44,478

41,503

Total current assets

510,867

191,490

NON-CURRENT ASSETS:

Operating lease right-of-use assets

2,861

3,424

Deferred tax assets

4,098

3,751

Long-term prepaid expenses and other assets

13,913

11,684

Total assets

$531,739

$210,349

LIABILITIES AND SHAREHOLDERS' EQUITY/(DEFICIT)

CURRENT LIABILITIES:

Accounts payable

$10,877

$15,222

Accrued expenses and other liabilities

8,984

9,214

Debt, current portion

—

17,523

Operating lease liabilities - current

2,054

2,110

Warrant liabilities

131,882

203,726

Total current liabilities

153,797

247,795

NON-CURRENT LIABILITIES:

Debt, non-current portion

50,476

14,110

Operating lease liabilities - non-current

779

1,292

Total liabilities

$205,052

$263,197

SHAREHOLDERS' EQUITY/(DEFICIT):

Ordinary shares, £0.008 par value; 134,923,295 and 96,085,785 shares authorized, issued and outstanding at March 31, 2026 and December 31, 2025, respectively

1,393

973

Additional paid-in capital

1,071,481

783,562

Accumulated other comprehensive loss

(14,795)

(14,789)

Accumulated deficit

(731,392)

(822,594)

Total shareholders' equity/(deficit)

326,687

(52,848)

Total liabilities and shareholders' equity/(deficit)

$531,739

$210,349

COMPASS PATHWAYS PLC

Condensed Consolidated Statements of Operations and Comprehensive Loss

(unaudited)

(in thousands, except share and per share amounts)

(expressed in U.S. Dollars, unless otherwise stated)

Three Months ended March 31,

2026

2025

OPERATING EXPENSES:

Research and development

$26,480

$30,880

General and administrative

16,424

18,736

Total operating expenses

42,904

49,616

Loss from operations:

(42,904)

(49,616)

OTHER INCOME (EXPENSE), NET:

Fair value change of warrant liabilities

130,916

19,460

Benefit from R&D tax credit

2,477

8,448

Interest income

2,419

2,386

Interest expense

(1,465)

(1,124)

Foreign exchange (losses) gains

(736)

2,133

Other income

484

803

Total other income, net

134,095

32,106

Income (loss) before income taxes

91,191

(17,510)

Income tax benefit (expense)

11

(354)

Net income (loss)

$91,202

$(17,864)

Net income (loss) per share attributable to ordinary shareholders: basic

$0.71

$(0.20)

Weighted average ordinary shares outstanding: basic

110,064,581

89,192,252

Net loss per share attributable to ordinary shareholders: diluted

$(0.30)

$(0.24)

Weighted average ordinary shares outstanding: diluted

130,266,693

98,641,623

Net income (loss)

$91,202

$(17,864)

Other comprehensive income (loss):

Foreign exchange translation adjustment

(6)

(117)

Comprehensive income (loss)

$91,196

$(17,981)

View source version on businesswire.com: https://www.businesswire.com/news/home/20260513826535/en/

-

WASHINGTON--(BUSINESS WIRE)--Easterly Government Properties, Inc. (NYSE: DEA) (the “Company” or “Easterly”), a fully integrated real estate investment trust focused primarily on the acquisition, development and management of Class A commercial properties leased to the U.S. Government and its adjacent partners, announced today that management will present at Nareit’s REITweek 2026 Investor Conference (the “Conference”) in New York, New York on June 2, 2026 from 9:30 – 10:00 AM Eastern Time. The Company will also participate in investor meetings from June 2 – 3, 2026.

For investors interested in listening to the presentation, the live audio-webcast will be provided in listen-only mode in the Presentation section of the Company’s Investor Relations website at ir.easterlyreit.com, and at the following link: Easterly Government Properties Webcast. A replay of the webcast will be available for 60 days following the presentation. Electronic copies of any materials to be provided to investors at the Conference will also be made available in the Presentation section of the Company’s Investor Relations website prior to the start of the Conference.

About Easterly Government Properties, Inc.

Easterly Government Properties, Inc. (NYSE: DEA) is based in Washington, D.C., and focuses primarily on the acquisition, development and management of Class A commercial properties that are leased to the U.S. Government and its adjacent partners. Easterly’s experienced management team brings specialized insight into the strategy and needs of mission-critical U.S. Government agencies for properties leased to such agencies either directly or through the U.S. General Services Administration (GSA). For further information on the company and its properties, please visit www.easterlyreit.com.

More News From Easterly Government Properties, Inc.

Back to Newsroom

REITs are looking increasingly compelling in the current environment. I detail my favorite 7%+ yielding REIT investment opportunities right now. I share the risks and the upside potential for both of them.

April 15, 2026 16:15 ET  | Source: Royalty Pharma plc

NEW YORK, April 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2026 financial results on Wednesday, May 6, 2026 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.

Conference Call Information

Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/events/ to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company's website for at least 30 days.

About Royalty Pharma

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, Servier’s Voranigo, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, and 19 development-stage product candidates. For more information, visit www.royaltypharma.com.

Royalty Pharma Investor Relations and Communications

+1 (212) 883-6637
[email protected]

April 21, 2026 13:00 ET  | Source: Royalty Pharma plc

NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the launch of the Royalty Pharma Translational Prize, which recognizes exceptional achievements in translational medicine. The Prize will honor scientific breakthroughs that bridge the gap between fundamental discovery and the development of new medicines that improve and extend patients’ lives. It will include a $1 million award distributed among one or more established scientists whose work has translated unique scientific insights into medicines with significant impact, particularly contributions not yet recognized by the field’s most prominent awards.

“Royalty Pharma believes that scientific discovery can transform patient lives when it is successfully translated into medicines,” said Pablo Legorreta, Chief Executive Officer and Chairman of the Board of Royalty Pharma. “With the Royalty Pharma Translational Prize, we aim to recognize and celebrate the scientists whose discoveries have crossed that crucial bridge - from insight to impact - and to highlight the importance of translational research in advancing human health.”

The Prize will be administered by Royalty Pharma and selected by an independent international committee of leading scientists and industry experts. The committee will be chaired by Sir Gregory Winter, Nobel Laureate in Chemistry and pioneer of antibody engineering whose work has led to multiple life‑saving therapies.

“The Royalty Pharma Translational Prize will help create a culture of translation in academia, encourage other people into the area and facilitate the creation of new medicines. By recognizing scientists whose work has demonstrably improved patient care, the Royalty Pharma Translational Prize underscores the essential role that translational research plays in turning promising discoveries into medicines.” said Sir Gregory Winter.

The Prize will be presented annually, with nominations opening in summer 2026. The first laureate will be recognized in spring 2027 at the Accelerating Bio‑Innovation (ABI) conference.

About Royalty Pharma

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, GSK’s Trelegy, Biogen’s Tysabri and Spinraza, Roche’s Evrysdi, Astellas and Pfizer’s Xtandi, Johnson & Johnson’s Tremfya, AbbVie and Johnson & Johnson’s Imbruvica, Servier’s Voranigo, Gilead’s Trodelvy, Amgen’s Imdelltra and Alnylam’s Amvuttra, among others, and 19 development-stage product candidates. For more information, visit www.royaltypharma.com.

About the Royalty Pharma Translational Prize

The Prize honors scientific breakthroughs that bridge the gap between fundamental discovery and the development of new medicines that improve and extend patients’ lives. It is awarded annually to one or more established scientists whose work has translated unique scientific insights into medicines with significant impact, particularly contributions not yet recognized by the field’s most prominent awards. For more information, visit www.rptranslationalprize.com.

About Accelerating Bio-Innovation

The Accelerating Bio-Innovation conference series was created by Royalty Pharma as a forum that bridges the worlds of academia, industry, and finance to gain new insights and inspire collaborations that will lead to new medicines. Alternating between the University of Cambridge UK and the Massachusetts Institute of Technology, the invitation-only ABI conference brings together life-science business leaders, renowned scientists, visionary entrepreneurs, and finance innovators. At the heart of each ABI conference is a curated program featuring world-class speakers, engaging social events, and high-impact networking opportunities, all designed to inspire dialogue, foster connections, and drive innovation in life sciences. For more information, visit www.abiconference.com.

Royalty Pharma Investor Relations and Communications

+1 (212) 883-6772
[email protected]

Portfolio Receipts growth of 10% to $925 million; Royalty Receipts growth of 13%Net cash provided by operating activities of $718 millionRaised full year 2026 guidance: Portfolio Receipts expected to be $3,325 million to $3,450 million NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2026 and raised full year 2026 guidance for Portfolio Receipts.

“Royalty Pharma has delivered a strong start to 2026 across multiple dimensions. We grew Royalty Receipts by 13% and announced up to $1.25 billion of royalty transactions in the first quarter,” said Pablo Legorreta, Royalty Pharma’s Chief Executive Officer and Chairman of the Board. “Importantly, we continue to innovate our business and are very excited by the emergence of a significant opportunity in R&D co-funding with global biopharma companies. Our transactions this year included two such agreements - with Johnson & Johnson and Teva - underscoring the growing demand for this novel funding modality. We were also delighted by positive clinical and regulatory developments across our portfolio, notably the unprecedented overall survival benefit for daraxonrasib in pancreatic cancer. Lastly, we took major steps to strengthen our capabilities in the Asia-Pacific region, Partnering and AI with the addition of key leaders to our team. As a result, we are incredibly well positioned as a premier capital allocator in life sciences to deliver consistent, compounding growth.”

Double-digit growth in Royalty Receipts and Portfolio Receipts

Royalty Receipts grew 13% to $887 million in the first quarter of 2026 driven by Tremfya, Voranigo and Evrysdi.Portfolio Receipts increased by 10% to $925 million. Strong transaction activity

Acquired three royalties for $1.25 billion in announced value; Capital Deployment of $528 million in the first quarter.R&D co-funding collaborations in immunology announced with Johnson & Johnson on JNJ-4804 and Teva on TEV-’408. Positive clinical and regulatory updates across royalty portfolio

Positive Phase 3 results for Revolution Medicines’ daraxonrasib in pancreatic cancer and Cytokinetics’ Myqorzo in non-obstructive hypertrophic cardiomyopathy.Denali’s Avlayah (tividenofusp alfa) approved by FDA (Hunter syndrome); Nuvalent’s neladalkib (lung cancer) New Drug Application submitted to FDA. Raising financial guidance for full year 2026 (excludes contribution from future transactions)

Royalty Pharma now expects 2026 Portfolio Receipts to be between $3,325 million and $3,450 million (previously $3,275 million to $3,425 million), representing expected Royalty Receipts growth of 4% to 8%. Financial & Liquidity Summary

 Three Months Ended March 31,($ and shares in millions; unaudited)20262025ChangePortfolio Receipts92583910%Net cash provided by operating activities71859620%Adjusted EBITDA (non-GAAP)*88973821%Portfolio Cash Flow (non-GAAP)*72261118%Weighted average Class A ordinary shares outstanding - diluted557578(4)% *See “Liquidity and Capital Resources” section. Adjusted EBITDA and Portfolio Cash Flow are non-GAAP liquidity measures calculated in accordance with the credit agreement.

2026 Financial Outlook

Royalty Pharma has provided guidance for full year 2026, excluding new transactions and borrowings announced after the date of this release, as follows:

 Provided May 6, 2026PreviousPortfolio Receipts$3,325 million to $3,450 million$3,275 million to $3,425 millionPayments for operating and professional costs5.5% to 6.5% of Portfolio Receipts5.5% to 6.5% of Portfolio ReceiptsInterest paid$350 million to $360 million$350 million to $360 million Portfolio Receipts is defined as the sum of Royalty Receipts and Milestones and other contractual receipts. The above Portfolio Receipts guidance provided on May 6, 2026 includes expected Royalty Receipts growth of 4% to 8% in 2026.

Royalty Pharma’s full year 2026 guidance reflects an estimated foreign exchange impact of approximately +1% to Portfolio Receipts, assuming current foreign exchange rates prevail for the rest of 2026.

Payments for operating and professional costs in 2026 are expected to decrease as a percentage of Portfolio Receipts, compared to 8.9% in 2025, primarily due to extinguishment of the management fee following the completion of the internalization transaction on May 16, 2025.

Total interest paid is based on the semi-annual interest payment schedule of Royalty Pharma’s existing notes and the quarterly interest payment schedule for the term loan assumed as part of the internalization transaction. In 2026, Royalty Pharma anticipates interest paid to be approximately $350 million to $360 million.(5) Interest paid in the third quarter of 2026 is anticipated to be approximately $175 million. De minimis amounts are anticipated in the second and fourth quarters of 2026. These projections assume no additional debt financing in 2026, including no drawdown on the revolving credit facility. In the first quarter of 2026, Royalty Pharma collected interest of $6 million on its cash and cash equivalents, which partially offset interest paid.

Royalty Pharma today provides this guidance based on its most up-to-date view of its prospects. This guidance assumes no major unforeseen adverse events or changes in foreign exchange rates and excludes the contributions from transactions announced subsequent to the date of this press release.

Portfolio Receipts Highlights

 Three Months Ended March 31,($ in millions; unaudited)20262025ChangeProducts:Marketers:Therapeutic Area:   Cystic fibrosis franchiseVertexRare disease2532501%TrelegyGSKRespiratory988515%EvrysdiRocheRare disease805351%TremfyaJohnson & JohnsonImmunology643679%TysabriBiogenNeuroscience5961(3)%XtandiPfizer, AstellasOncology5152(3)%VoranigoServierOncology4720140%ImbruvicaAbbVie, Johnson & JohnsonOncology3846(17)%Cabometyx/CometriqExelixis, Ipsen, TakedaOncology23219%PromactaNovartisHematology1744(61)%ImdelltraAmgenOncology17—n/aTrodelvyGileadOncology13137%SpinrazaBiogenRare disease1213(9)%AmvuttraAlnylamRare disease8—n/aOther products(6)1089612%Royalty Receipts88778813%Milestones and other contractual receipts3851(25)%Portfolio Receipts92583910% Amounts shown in the table may not add due to rounding.

Royalty Receipts was $887 million in the first quarter of 2026, an increase of 13% compared to $788 million in the first quarter of 2025. The increase was primarily driven by Tremfya, Voranigo and Evrysdi, partially offset by a decline from Promacta due to U.S. generic competition. Royalty Receipts from Evrysdi included the benefit of the additional royalties acquired in December 2025.

Portfolio Receipts was $925 million in the first quarter of 2026, an increase of 10% compared to $839 million in the first quarter of 2025, primarily driven by the same Royalty Receipts increases noted above, partially offset by lower Milestones and other contractual receipts.

Liquidity and Capital Resources

Royalty Pharma’s liquidity and capital resources are summarized below:

As of March 31, 2026, Royalty Pharma had cash and cash equivalents of $586 million and total debt with principal value of $9.2 billion.

In the first quarter of 2026, Royalty Pharma paid a quarterly dividend of $0.235 per share, equating to $136 million in dividends and distributions.

In January 2025, Royalty Pharma announced a share repurchase program under which it may repurchase up to $3.0 billion of its Class A ordinary shares. Royalty Pharma repurchased approximately 1.1 million Class A ordinary shares for $50 million in the first quarter of 2026. The weighted-average number of diluted Class A ordinary shares outstanding for the first quarter of 2026 was 557 million, a decline of 4% as compared to 578 million for the first quarter of 2025.

Liquidity Summary

 Three Months Ended March 31,($ in millions; unaudited)2026 2025 Portfolio Receipts925 839 Payments for operating and professional costs(36)(102)Adjusted EBITDA (non-GAAP)889 738 Interest paid, net(167)(127)Portfolio Cash Flow (non-GAAP)722 611  Amounts may not add due to rounding.

Adjusted EBITDA (non-GAAP) was $889 million in the first quarter of 2026. Adjusted EBITDA is calculated as Portfolio Receipts minus payments for operating and professional costs.Portfolio Cash Flow (non-GAAP) was $722 million in the first quarter of 2026. Portfolio Cash Flow is calculated as Adjusted EBITDA minus interest paid or received, net. This measure reflects the cash generated by Royalty Pharma’s business that can be redeployed into value-enhancing royalty acquisitions, used to repay debt, returned to shareholders through dividends or share purchases, or utilized for other discretionary investments. Refer to Table 4 for Royalty Pharma’s reconciliation of each non-GAAP measure to the most directly comparable GAAP financial measure, net cash provided by operating activities.

Capital Deployment reflects cash payments during the period for new and previously announced transactions. Capital Deployment was $528 million in the first quarter of 2026, consisting primarily of upfront payments for the Ziihera (see ‘Royalty Transactions’) and Avlayah (formerly known as tividenofusp alfa) transactions and a milestone payment related to Trelegy.

The table below details Capital Deployment by category:

Capital Deployment

 Three Months Ended March 31,($ in millions; unaudited)2026 2025 Acquisitions of financial royalty assets(452)(1)Development-stage funding payments(26)(51)Milestone payments(50)(50)Contributions from legacy non-controlling interests - R&D— 0 Capital Deployment(528)(101) Amounts may not add due to rounding.

Royalty Transactions

During the first quarter of 2026, Royalty Pharma announced new transactions of up to $1.25 billion, which reflects the entire amount of potential capital committed for new transactions, including potential future milestones.

Recent transactions include:

In March 2026, Royalty Pharma entered into an R&D co-funding arrangement with Johnson & Johnson to provide $500 million over two years for the development of JNJ‑4804, an investigational medicine for autoimmune diseases.In March 2026, Royalty Pharma acquired a royalty interest in Ziihera from Zymeworks Inc. for $250 million. Ziihera, which is marketed by Jazz Pharmaceuticals and BeOne Medicines, is approved for human epidermal growth factor receptor 2 (HER2)-positive metastatic biliary tract cancer and is in development for HER2-positive gastric cancer.In January 2026, Royalty Pharma announced a funding agreement with Teva Pharmaceuticals for TEV-’408 for up to $500 million. The agreement includes up to $75 million to co-fund a Phase 2b study for vitiligo targeted for 2026. Based on the results of this study, Royalty Pharma has the option to provide up to an additional $425 million to co-fund the Phase 3 development program. The information in this section should be read together with Royalty Pharma’s reports and documents filed with the SEC at www.sec.gov and the reader is also encouraged to review all other press releases and information available in the Investors section of Royalty Pharma’s website at www.royaltypharma.com.

Key Developments Relating to the Portfolio

The key developments related to Royalty Pharma’s royalty interests are discussed below based on disclosures from the marketers of the products.

MyqorzoIn May 2026, Cytokinetics announced positive topline results from ACACIA-HCM, the pivotal phase 3 clinical trial of Myqorzo in patients with non-obstructive hypertrophic cardiomyopathy. ACACIA-HCM met both dual primary endpoints, demonstrating statistically significant improvements from baseline to week 36 compared to placebo.In February 2026, Cytokinetics announced that the European Commission (EC) approved Myqorzo for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients.

ZiiheraIn April 2026, Jazz Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) accepted for filing, with Priority Review, a supplemental Biologics License Application for Ziihera in combination regimens for the first line treatment of adult patients with HER2-positive metastatic gastroesophageal adenocarcinoma. The FDA has set a Prescription Drug User Fee Act target action date of August 25, 2026.daraxonrasibIn April 2026, Revolution Medicines announced positive Phase 3 results from the RASolute 302 trial evaluating daraxonrasib in patients with previously treated metastatic pancreatic cancer. Based on these results, Revolution Medicines intends to submit the data to global regulatory authorities, including the FDA, as part of a future New Drug Application (NDA) under the Commissioner’s National Priority Voucher program.neladalkibIn April 2026, Nuvalent announced the submission of an NDA to the FDA for neladalkib, an investigational anaplastic lymphoma kinase (ALK)‑selective inhibitor, for tyrosine kinase inhibitor pre‑treated advanced ALK‑positive non-small cell lung cancer.SpinrazaIn March 2026, Biogen announced that the FDA approved the high dose regimen of Spinraza for spinal muscular atrophy (SMA).In January 2026, Biogen announced that the EC granted marketing authorization for a high dose regimen of Spinraza for SMA.

litifilimabIn March 2026, Biogen reported positive Phase 2 results from the AMETHYST Phase 2/3 study (Part A) of litifilimab in cutaneous lupus erythematosus (CLE), demonstrating reductions in skin disease activity through week 24.In January 2026, Biogen announced that the FDA granted Breakthrough Therapy Designation for litifilimab for the treatment of CLE.

AvlayahIn March 2026, Denali Therapeutics announced that the FDA granted accelerated approval of Avlayah (tividenofusp alfa) for the treatment of Hunter syndrome. Avlayah is the first FDA-approved biologic specifically designed to cross the blood-brain barrier and reach the whole body, including the brain.TazverikIn March 2026, Ipsen announced that it was voluntarily withdrawing Tazverik from all Ipsen markets based on emerging data from the ongoing Phase Ib/III SYMPHONY-1 trial. In addition, Eisai announced plans to discontinue sales of Tazverik in Japan. In the first quarter of 2026, Royalty Pharma recorded $69 million of non-cash impairment charges related to Tazverik.ampreloxetineIn March 2026, Theravance Biopharma reported that the Phase 3 CYPRESS study evaluating ampreloxetine in patients with symptomatic neurogenic orthostatic hypotension due to multiple system atrophy did not meet the primary endpoint. As a result, Theravance will wind down the ampreloxetine program.TEV-’749In February 2026, Teva Pharmaceuticals announced that the FDA accepted the NDA for olanzapine extended-release injectable suspension (TEV-'749) for the treatment of schizophrenia in adults.pelabresibIn January 2026, Novartis announced plans to submit a European Union regulatory filing for pelabresib in 2026, and that it would begin a new Phase 3 study in the United States, China and Japan.obexelimabIn January 2026, Zenas BioPharma announced positive results from the Phase 3 INDIGO trial of obexelimab in Immunoglobulin G4-related disease (IgG4-RD), which met the primary endpoint demonstrating a clinically meaningful and highly statistically significant reduction in risk of IgG4-RD flare. Zenas anticipates submitting a Biologics License Application in Q2 2026 and a Marketing Authorization Application to the European Medicines Agency in the second half of 2026. Financial Results Call

Royalty Pharma will host a conference call and simultaneous webcast to discuss its first quarter 2026 results today at 8:00 a.m., Eastern Time. Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/events to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company’s website for at least 30 days.

About Royalty Pharma plc

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, GSK’s Trelegy, Biogen’s Tysabri and Spinraza, Roche’s Evrysdi, Astellas and Pfizer’s Xtandi, Johnson & Johnson’s Tremfya, AbbVie and Johnson & Johnson’s Imbruvica, Servier’s Voranigo, Gilead’s Trodelvy, Amgen’s Imdelltra and Alnylam’s Amvuttra, among others, and 19 development-stage product candidates.

Forward-Looking Statements

The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This document contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of Royalty Pharma’s strategies, financing plans, growth opportunities, market growth and plans for capital deployment, plus the benefits of the internalization transaction, including expected accretion, enhanced alignment with shareholders, increased investment returns, expectations regarding management continuity, transparency and governance, and the benefits of simplification to its structure. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of Royalty Pharma’s performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, and other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this document are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

Certain information contained in this document relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the company’s own internal estimates and research. While the company believes these third-party sources to be reliable as of the date of this document, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this document involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the company believes its own internal research is reliable, such research has not been verified by any independent source.

For further information, please reference Royalty Pharma’s reports and documents filed with the U.S. Securities and Exchange Commission (“SEC”) by visiting EDGAR on the SEC’s website at www.sec.gov.

Portfolio Receipts

Portfolio Receipts is a key performance metric that represents Royalty Pharma’s ability to generate cash from Royalty Pharma’s portfolio investments, the primary source of capital that is deployed to make new portfolio investments. Portfolio Receipts is defined as the sum of Royalty Receipts and Milestones and other contractual receipts. Royalty Receipts includes variable payments based on sales of products, net of contractual payments to the legacy non-controlling interests, that are attributed to Royalty Pharma.

Milestones and other contractual receipts include sales-based or regulatory milestone payments and other fixed contractual receipts, net of contractual payments to legacy non-controlling interests, that are attributed to Royalty Pharma. Portfolio Receipts does not include royalty receipts and milestones and other contractual receipts that were received on an accelerated basis under the terms of the agreement governing the receipt or payment. Portfolio Receipts also does not include proceeds from equity securities or proceeds from purchases and sales of marketable securities, both of which are not central to Royalty Pharma’s fundamental business strategy. 2025 Portfolio Receipts does not include the $511 million of proceeds from the sale of the MorphoSys Development Funding Bonds, as the transaction was treated as an asset sale.

Portfolio Receipts is calculated as the sum of the following line items from Royalty Pharma’s GAAP condensed consolidated statements of cash flows: Cash collections from financial royalty assets, Cash collections from intangible royalty assets, Other royalty cash collections, Proceeds from available for sale debt securities and Distributions from equity method investees less Distributions to legacy non-controlling interests - Portfolio Receipts, which represent contractual distributions of Royalty Receipts, milestones and other contractual receipts to the Legacy Investors Partnerships.

Use of Non-GAAP Measures

Adjusted EBITDA and Portfolio Cash Flow are non-GAAP liquidity measures that exclude the impact of certain items and therefore have not been calculated in accordance with GAAP. Management believes that Adjusted EBITDA and Portfolio Cash Flow are important non-GAAP measures used to analyze liquidity because they are key components of certain material covenants contained within Royalty Pharma’s credit agreement. Royalty Pharma cautions readers that amounts presented in accordance with the definitions of Adjusted EBITDA and Portfolio Cash Flow may not be the same as similar measures used by other companies or analysts. These non-GAAP liquidity measures have limitations as analytical tools, and you should not consider them in isolation or as a substitute for the analysis of Royalty Pharma’s results as reported under GAAP.

The definitions of Adjusted EBITDA and Portfolio Cash Flow used by Royalty Pharma are the same as the definitions in the credit agreement. Noncompliance with the interest coverage ratio, leverage ratio and Portfolio Cash Flow ratio covenants under the credit agreement could result in lenders requiring the company to immediately repay all amounts borrowed. If Royalty Pharma cannot satisfy these covenants, it would be prohibited under the credit agreement from engaging in certain activities, such as incurring additional indebtedness, paying dividends, making certain payments, and acquiring and disposing of assets. Consequently, Adjusted EBITDA and Portfolio Cash Flow are critical to the assessment of Royalty Pharma’s liquidity.

Adjusted EBITDA and Portfolio Cash Flow are used by management as key liquidity measures in the evaluation of the company’s ability to generate cash from operations. Management uses Adjusted EBITDA and Portfolio Cash Flow when considering available cash, including for decision-making purposes related to funding of acquisitions, debt repayments, dividends and other discretionary investments. Further, these non-GAAP liquidity measures help management, the audit committee and investors evaluate the company’s ability to generate liquidity from operating activities.

The company has provided reconciliations of these non-GAAP liquidity measures to the most directly comparable GAAP financial measure, being net cash provided by operating activities in Table 4.

Royalty Pharma Investor Relations and Communications

+1 (212) 883-6772
[email protected]

Royalty Pharma plc
Condensed Consolidated Statements of Operations(8)(unaudited)
Table 1   Three Months Ended March 31,($ in millions)2026
2025
Income and other revenues  Income from financial royalty assets595 539 Other royalty income and revenues36 29 Total income and other revenues631 568 Operating (income)/expense  Provision for changes in expected cash flows from financial royalty assets(197)(127)Provision for credit losses on unfunded commitments(4)— Research and development funding expense40 51 General and administrative expenses (includes 122 and 1 of share-based compensation expense for the three months ended March 31, 2026 and 2025, respectively)159 111 Financial royalty asset impairment69 — Total operating expense, net68 34 Operating income563 534 Other (income)/expense  Equity in earnings of equity method investees(22)(6)Interest expense94 65 Other expense, net23 41 Total other expense, net95 100 Consolidated net income before tax468 434 Income tax expense— — Consolidated net income468 434 Net income attributable to non-controlling interests174 195 Net income attributable to Royalty Pharma plc295 239  Amounts may not add due to rounding.

Royalty Pharma plc
Selected Balance Sheet Data (unaudited)
Table 2   ($ in millions)As of March 31, 2026As of December 31, 2025Cash and cash equivalents586619Total current and non-current financial royalty assets, net17,32217,063Total assets19,81519,621Current portion of long-term debt380380Long-term debt, net of current portion8,5768,571Total liabilities9,8799,906Total shareholders’ equity9,9379,715 Royalty Pharma plc
Condensed Consolidated Statements of Cash Flows (unaudited)
Table 3   Three Months Ended March 31,($ in millions)2026 2025 Cash flows from operating activities:  Cash collections from financial royalty assets916 830 Cash collections from intangible royalty assets4 0 Other royalty cash collections34 32 Distributions from equity method investees4 13 Interest received6 12 Development-stage funding payments(26)(51)Payments for operating and professional costs(36)(102)Payments for Employee EPAs(10)— Interest paid(174)(139)Net cash provided by operating activities718 596 Cash flows from investing activities:  Distributions from equity method investees42 36 Purchases of equity securities(23)(4)Proceeds from equity securities0 — Proceeds from available for sale debt securities4 13 Proceeds from sales of available for sale debt securities— 511 Acquisitions of financial royalty assets(452)(1)Milestone payments(50)(50)Net cash (used in)/provided by investing activities(478)504 Cash flows from financing activities:  Distributions to legacy non-controlling interests - Portfolio Receipts(78)(85)Distributions to continuing non-controlling interests(40)(54)Dividends to shareholders(104)(95)Repurchases of Class A ordinary shares(50)(709)Contributions from legacy non-controlling interests - R&D— 0 Contributions from non-controlling interests - other— 1 Other(0)— Net cash used in financing activities(273)(941)Net change in cash and cash equivalents(32)159 Cash and cash equivalents, beginning of period619 929 Cash and cash equivalents, end of period586 1,088  EPAs: Equity Performance Awards. Amounts may not add due to rounding.

Royalty Pharma plc
GAAP to Non-GAAP Reconciliation (unaudited)
Table 4   Three Months Ended March 31,($ in millions)2026 2025 Net cash provided by operating activities (GAAP)718 596 Adjustments:  Proceeds from available for sale debt securities(7)4 13 Distributions from equity method investees(7)42 36 Interest paid, net(7)167 127 Development-stage funding payments26 51 Distributions to legacy non-controlling interests - Portfolio Receipts(7)(78)(85)Payments for Employee EPAs10 — Adjusted EBITDA (non-GAAP)889 738 Interest paid, net(7)(167)(127)Portfolio Cash Flow (non-GAAP)722 611  EPAs: Equity Performance Awards. Amounts may not add due to rounding.

Royalty Pharma plc
Description of Approved Indications for Select Portfolio Therapies
Table 5
Cystic fibrosis franchise
Cystic fibrosisTrelegyChronic obstructive pulmonary disease and asthmaEvrysdiSpinal muscular atrophyTremfyaPlaque psoriasis, psoriatic arthritis, ulcerative colitis and Crohn’s diseaseTysabriRelapsing forms of multiple sclerosisXtandiProstate cancerVoranigoLow-grade gliomaImbruvicaHematological malignancies and chronic graft versus host diseaseCabometyx/CometriqKidney, liver and thyroid cancerPromactaChronic immune thrombocytopenia purpura and aplastic anemiaImdelltraSmall cell lung cancerTrodelvyBreast cancerSpinrazaSpinal muscular atrophyAmvuttraTransthyretin amyloidosis   Notes
 (1)Portfolio Receipts is defined above in the section entitled “Portfolio Receipts.”(2)  Adjusted EBITDA is defined under the credit agreement as Portfolio Receipts minus payments for operating and professional costs. Operating and professional costs reflect Payments for operating and professional costs from the GAAP condensed consolidated statements of cash flows. See GAAP to Non-GAAP reconciliation in Table 4.(3)Portfolio Cash Flow is defined under the credit agreement as Adjusted EBITDA minus interest paid or received, net. See GAAP to Non-GAAP reconciliation in Table 4. Portfolio Cash Flow reflects the cash generated by Royalty Pharma’s business that can be redeployed into value-enhancing royalty acquisitions, used to repay debt, returned to shareholders through dividends or share purchases or utilized for other discretionary investments.(4)Capital Deployment is calculated as the summation of the following line items from Royalty Pharma’s GAAP condensed consolidated statements of cash flows: Investments in equity method investees, Purchases of available for sale debt securities, Acquisitions of financial royalty assets, Acquisitions of other financial assets, Milestone payments, Development-stage funding payments less Contributions from legacy non-controlling interests - R&D.(5)The term loan that Royalty Pharma assumed as part of the Internalization has a Secured Overnight Financing Rate (SOFR) based variable interest rate. Royalty Pharma estimated the related interest payment for 2026 based on the forward curve as of April 29, 2026.(6)Other products primarily include Royalty Receipts on the following products: Crysvita, Emgality, Erleada, Farxiga/Onglyza, IDHIFA, Niktimvo, Nurtec ODT, Orladeyo, Skytrofa, Soliqua, Yorvipath and distributions from the Legacy SLP Interest, which is presented as Distributions from equity method investees on the GAAP condensed consolidated statements of cash flows.(7)The table below shows the line item for each adjustment and the direct location for such line item on the GAAP condensed consolidated statements of cash flows. Reconciling AdjustmentStatements of Cash Flows ClassificationInterest paid, netOperating activities (Interest paid less Interest received)Distributions from equity method investeesInvesting activitiesProceeds from available for sale debt securitiesInvesting activitiesDistributions to legacy non-controlling interests - Portfolio ReceiptsFinancing activities (8)The condensed consolidated statement of operations for 2025 has been recast to reflect the adoption of ASU 2025-07 by removing the losses previously recognized on derivative.

Have you been paying attention to shares of Royalty Pharma (RPRX - Free Report) ? Shares have been on the move with the stock up 7.6% over the past month. The stock hit a new 52-week high of $50.82 in the previous session. Royalty Pharma has gained 30.5% since the start of the year compared to the -7.3% gain for the Zacks Medical sector and the -1.6% return for the Zacks Medical - Biomedical and Genetics industry.

What's Driving the Outperformance?The stock has an impressive record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last four quarters. In its last earnings report on May 6, 2026, Royalty Pharma reported EPS of $1.3 versus consensus estimate of $1.22 while it beat the consensus revenue estimate by 5.95%.

For the current fiscal year, Royalty Pharma is expected to post earnings of $5.08 per share on $3.45 in revenues. This represents a 5.18% change in EPS on a 5.95% change in revenues. For the next fiscal year, the company is expected to earn $5.41 per share on $3.63 in revenues. This represents a year-over-year change of 6.35% and 5.36%, respectively.

Valuation MetricsThough Royalty Pharma has recently hit a 52-week high, what is next for Royalty Pharma? A key aspect of this question is taking a look at valuation metrics in order to determine if the company has run ahead of itself.

On this front, we can look at the Zacks Style Scores, as these give investors a variety of ways to comb through stocks (beyond looking at the Zacks Rank of a security). These styles are represented by grades running from A to F in the categories of Value, Growth, and Momentum, while there is a combined VGM Score as well. The idea behind the style scores is to help investors pick the most appropriate Zacks Rank stocks based on their individual investment style.

Royalty Pharma has a Value Score of B. The stock's Growth and Momentum Scores are C and C, respectively, giving the company a VGM Score of B.

In terms of its value breakdown, the stock currently trades at 9.9X current fiscal year EPS estimates, which is not in-line with the peer industry average of 21.7X. On a trailing cash flow basis, the stock currently trades at 10.6X versus its peer group's average of 13.9X. Additionally, the stock has a PEG ratio of 3.22. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective.

Zacks RankWe also need to consider the stock's Zacks Rank, as this is even more important than the company's VGM Score. Fortunately, Royalty Pharma currently has a Zacks Rank of #2 (Buy) thanks to rising earnings estimates.

Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Royalty Pharma passes the test. Thus, it seems as though Royalty Pharma shares could have potential in the weeks and months to come.

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Royalty Pharma (RPRX - Free Report) and Amgen (AMGN - Free Report) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.

Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits.

Royalty Pharma has a Zacks Rank of #2 (Buy), while Amgen has a Zacks Rank of #3 (Hold) right now. Investors should feel comfortable knowing that RPRX likely has seen a stronger improvement to its earnings outlook than AMGN has recently. But this is only part of the picture for value investors.

Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels.

The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value.

RPRX currently has a forward P/E ratio of 9.92, while AMGN has a forward P/E of 14.84. We also note that RPRX has a PEG ratio of 3.22. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. AMGN currently has a PEG ratio of 3.35.

Another notable valuation metric for RPRX is its P/B ratio of 3. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. By comparison, AMGN has a P/B of 19.35.

These metrics, and several others, help RPRX earn a Value grade of B, while AMGN has been given a Value grade of C.

RPRX is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. And, based on the above valuation metrics, we feel that RPRX is likely the superior value option right now.

Royalty Pharma plc (RPRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Royalty Pharma plc (RPRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Royalty Pharma plc (RPRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

, /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Paysafe Limited (NYSE: PSFE) between March 4, 2025 and November 12, 2025, inclusive (the "Class Period"), of the important April 7, 2026 lead plaintiff deadline.

So What: If you purchased Paysafe securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Paysafe class action, go to https://rosenlegal.com/submit-form/?case_id=2745 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 7, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases.  Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Paysafe's ecommerce business had significant exposure to a single high risk client; (2) as a result, Paysafe's credit loss reserves and/or write-offs were understated; (3) Paysafe had an undisclosed issue with higher risk Merchant Category Codes, making its client services difficult to bank; (4) the foregoing issues were likely to have a material negative impact on Paysafe's revenue growth and overall revenue mix; (5) as a result, Paysafe was unlikely to meet its own previously issued financial guidance for fiscal year 2025; and (6) as a result of the foregoing, defendants' positive statements about Paysafe's  business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Paysafe class action, go to https://rosenlegal.com/submit-form/?case_id=2745 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

     Laurence Rosen, Esq.
     Phillip Kim, Esq.
     The Rosen Law Firm, P.A.
     275 Madison Avenue, 40th Floor
     New York, NY 10016
     Tel: (212) 686-1060
     Toll Free: (866) 767-3653
     Fax: (212) 202-3827
     [email protected]
     www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

, /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Paysafe Limited (NYSE: PSFE).

Shareholders who purchased shares of PSFE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:
https://securitiesclasslaw.com/securities/paysafe-limited-loss-submission-form/?id=185254&from=4 

CLASS PERIOD: March 4, 2025 to November 12, 2025

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) Paysafe's ecommerce business had significant exposure to a single high risk client; (2) as a result, the Company's credit loss reserves and/or write-offs were understated; (3) Paysafe had an undisclosed issue with higher risk merchant category codes, making its client services difficult to bank; (4) foregoing issues were likely to have a material negative impact on the Company's revenue growth and overall revenue mix; (5) as a result, Paysafe was unlikely to meet its own previously issued financial guidance for fiscal year 2025; and (6) that, as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

DEADLINE: April 7, 2026 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/paysafe-limited-loss-submission-form/?id=185254&from=4

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of PSFE during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is April 7, 2026. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

SOURCE The Gross Law Firm

By PYMNTS  |  April 7, 2026

 | 

Global payments platform Paysafe now enables iGaming operators and daily fantasy sports brands in the U.S. market to accept crypto payments.

The company’s new Pay with Crypto payment method lets iGaming brands’ customers fund their player accounts with stablecoins or cryptocurrency, where permitted, and then converts that crypto deposit to U.S. dollars to allow play, Paysafe said in a Tuesday (April 7) press release.

The solution is powered by global crypto payments and stablecoin infrastructure firm MoonPay, according to the release.

For operators, Pay with Crypto offers a choice of settling payment almost instantly in stablecoins in their business’s crypto wallet or settling in U.S. dollars or any major fiat currency, per the release.

The use of cryptocurrency is evolving from investment to payments, Zak Cutler, president of global gaming at Paysafe, said in the release.

“Against this backdrop, we’re delighted to unveil Pay with Crypto, a forward-thinking solution that strongly positions U.S. operators for their customers’ changing transactional preferences — the future of how they pay when they play,” Cutler said.

Advertisement: Scroll to Continue

MoonPay Founder and CEO Ivan Soto-Wright said in the release that crypto rails make payments faster and more efficient.

“People shouldn’t have to convert their digital assets just to make a purchase — they want to use what they already have,” Soto-Wright said. “Paysafe brings that experience to more people through trusted, regulated platforms.”

Pay with Crypto joins several other payment methods enabled by Paysafe Gateway, which was developed specifically for iGaming. Paysafe Gateway also enables card payments, the Skrill digital wallet, the PaysafeCash eCash solution, a Pay by Bank product and more than 30 local payment methods, according to the release.

Payments increasingly sit at the center of a makeover of the sector in which sportsbooks and online gaming platforms compete for player loyalty, Cutler told PYMNTS in an interview posted in February 2025.

“Payments aren’t just a back-end function — they’re a strategic growth driver,” Cutler said. “The more seamless the process, the higher the conversion, retention and overall user satisfaction. That’s where the industry is headed.”

Paysafe reported in March that volumes in iGaming during the U.S. football season reached record levels, underscoring steady demand in entertainment-driven categories.

In 2025, the company’s North American iGaming business saw 50% processing revenue growth, Paysafe said in a March 3 earnings report.

, /PRNewswire/ -- MoonPay, the global leader in crypto payments and stablecoin infrastructure, is now powering crypto payments inside Paysafe (NYSE: PSFE), a global payments platform that processed $167 billion in transactions in 2025. The integration embeds stablecoin rails directly into Paysafe's platform, giving merchants crypto payment capability alongside cards, digital wallets, eCash, bank transfers, and local payment rails.

The first product to launch from the partnership is Pay with Crypto, which allows brands' customers to use their preferred stablecoin or cryptocurrency to fund their accounts, where permitted. Whether a customer wants to fund an account using USD Coin (USDC), another stablecoin, or any major cryptocurrency, Paysafe's new payment option for operators' cashiers enables their crypto deposit to be rapidly converted to U.S. dollars. The solution supports e-commerce, financial services, retail, and iGaming and daily fantasy sports operators, among other verticals.

Ivan Soto-Wright, Founder and CEO of MoonPay, commented: "Crypto rails are making payments faster and cheaper, and our job is to close the gap between this technology and real-world utility."

Crypto as a Payments Rail

The integration reflects a broader shift in how stablecoin infrastructure scales. Rather than going direct-to-consumer, MoonPay is powering the crypto capability of an established payment processor, embedding stablecoin rails into traditional checkout flows. For merchants, that means gaining crypto payment functionality through Paysafe without requiring a separate integration.

Zak Cutler, President of Global Gaming at Paysafe, said: "Galvanized by the growing popularity of stablecoins, cryptocurrency is evolving in the U.S. from an investment asset into a unit of value for payments, and we're seeing this shift gather pace in the country's online gaming market. Against this backdrop, we're delighted to unveil Pay with Crypto, a forward-thinking solution that strongly positions U.S. operators for their customers' changing transactional preferences – the future of how they pay when they play."

How Pay with Crypto Works

After selecting Pay with Crypto and their preferred stablecoin or cryptocurrency, users simply connect their crypto or custodial wallet to fund the deposit, with the MoonPay Commerce Checkouts technology also supporting transactions via QR code using users' phones. Once transactions have been verified, Pay with Crypto instantly converts crypto deposits into U.S. dollars to fund the user's account.

For a daily fantasy sports operator, that means a player can fund their account with a stablecoin in seconds, expanding available deposit options without any additional integration work.

The flexibility embedded in the Pay with Crypto solution also extends to operators, which can choose to settle payments almost instantly in stablecoins in their business's crypto wallet, or settle in U.S. dollars or any major fiat currency through MoonPay's Virtual Accounts powered by Iron.

Disclaimer
Neither Paysafe nor any of its affiliates endorse or promote any form of wagering or gambling. Please note that all forms of gambling and betting (online and otherwise) carry with them inherent financial risk and risk of financial loss. Any gambling or betting activities should be exercised responsibly and with moderation in compliance with all applicable laws and regulations.

About Paysafe
Paysafe is a global payments platform powering the experience economy, with a strong focus on the iGaming, video gaming, e-commerce, online trading, retail, travel and hospitality sectors. With 30 years of expertise in payment technology, Paysafe helps businesses and consumers lift every experience through seamless, secure payment solutions, including card payments, digital wallets such as Skrill, eCash solutions like PaysafeCard, and a suite of local payment methods. With approximately 2,800 employees across 12 countries and annualized transactional volume of $167 billion in 2025, Paysafe connects people and businesses worldwide through innovative digital payment experiences. Further information is available at www.paysafe.com

About MoonPay
Founded in 2019, MoonPay is a global financial technology company that helps businesses and consumers move value across fiat and digital assets. MoonPay has more than 30 million customers across 180 countries and supports more than 500 enterprise customers spanning crypto and fintech.

MoonPay powers ramps, trading, commerce, and stablecoin infrastructure, connecting traditional payment rails with blockchains. MoonPay maintains a broad regulatory footprint, including a New York BitLicense, a New York Limited Purpose Trust Charter, and money transmitter licenses across the United States, as well as MiCA authorization in the EU.

MoonPay is how the world moves value. 

For media enquiries, contact:
[email protected]

SOURCE MoonPay